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Early mortality is high in hemodialysis (HD) patients, but little
is known about early cardiovascular event (CVE) rates after
HD initiation. To study this we analyzed data in the AROii
cohort of incident HD patients from over 300 European
Fresenius Medical Care dialysis centers. Weekly rates of a
composite of CVEs during the first year and monthly rates
of the composite and its constituents (coronary artery,
cerebrovascular, peripheral arterial, congestive heart failure,
and sudden cardiac death) during the first 2 years after HD
initiation were assessed. Of 6308 patients that started dialysis
within 7 days, 1449 patients experienced 2405 CVEs over the
next 2 years. The first-year CVE rate (30.2/100 person-years;
95% CI, 28.7–31.7) greatly exceeded the second-year rate
(19.4/100; 95% CI, 18.1–20.8). Composite CVEs were highest
during the first week with increased risk compared with the
second year, persisting until the fifth month. Except for
sudden cardiac death, temporal patterns of rates for all CVE
categories were very similar, with highest rates during the
first month and a high-risk period extending to 4 months.
Higher or lower cumulative weekly dialysis dose, lower blood
flow, and lower net ultrafiltration during dialysis were
associated with CVE during the high-risk period, but not
during the post high-risk period. Thus, the incidence of CVE
in the first weeks after HD initiation is much higher than
during subsequent periods which raises concerns that HD
initiation may trigger CVEs.
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In patients with chronic kidney disease (CKD) the first months
on hemodialysis (HD) have been identified as a high-risk
period for patient survival.1 In both the US2–7 and Europe,7–9
increased mortality during the first 3 months after dialysis initia-
tion, compared with subsequent periods, has been observed. The
underlying reasons remain poorly understood. Early dialysis
withdrawal may contribute to early mortality,3 but withdrawal
practice varies significantly across countries and overall accounts
for a comparatively small proportion of early death.7 Among
other causes of death, up to 40% have been attributed to cardio-
vascular (CV) disease8,9 and a large study found the greatest
difference between mortality rates during the first 3 months and
during the remainder of the first year on dialysis for CV-related
deaths.3 Thus, study of CV events (CVE) after dialysis initiation
should lead to a better understanding of the causes of early
mortality, risk prediction, and preventive strategies in high-risk
patients. However, there is a paucity of data on CVE rates
following HD initiation. In particular, it is not known whether
the time to event varies for specific CVE categories, whether CVE
risk factors vary for different CVE categories, and whether CVE
risk factors differ for early and subsequent periods on dialysis.
The clinical circumstances of dialysis initiation vary,
making analysis of the early time period after starting dialysis
challenging. Although many patients will initiate HD in an
outpatient setting, others will have their first dialysis during a
hospitalization period and will be subsequently referred to
dialysis centers after variable time periods. Thus, important
clinical events may easily be missed in registries of chronic
HD patients. In fact, because of these circumstances and
additional administrative reasons, many large registries do not
capture clinical data on the first months on HD.10 Smaller
studies, on the other hand, may have been of insufficient size
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to provide reliable rate estimates for different CVEs,11,12
although they have been important in characterizing early
mortality after dialysis initiation.
Utilizing data collected prospectively as part of the ARO
(Analyzing data, Recognizing excellence, and Optimizing
outcomes) CKD research initiative,13 we studied the occur-
rence of CVE after dialysis initiation in a large cohort of
incident HD patients at over 300 Fresenius Medical Care
dialysis centres in Europe (FME; ‘AROii’). Inclusion criteria
for the current study were carefully chosen, and different
scenarios for patients initiating HD within and outside the
FME network were considered to reliably capture early events.
RESULTS
Study population
The AROii cohort includes 11,244 incident patients present-
ing to FME centers in 14 European countries and Turkey.
Patients most frequently initiated HD on the day of study
enrollment (n= 3974) or within a week of this date (n= 2270),
whereas ~ 40% (n= 4882) initiated HD at an earlier time point
and a small proportion at later time points (n= 118; see Supple-
mentary Figure S1 online). For the purpose of the current study
we chose to exclude patients with a dialysis vintage of ⩾ 7 days
(n= 4569) and patients who did not initiate dialysis within
365 days of admission to FME (n= 21). Furthermore, we
excluded sequentially patients with no dialysis data (n= 484) or
with a history of kidney transplantation (n= 83), thus resulting
in a study cohort of 6308 patients. Within this study cohort
4005 patients (63%) initiated dialysis within FME facilities and
the remainder initiated dialysis elsewhere.
Patient characteristics
A total of 2405 CVEs were reported in 1449 patients (23% of
the study cohort) within 2 years after initiation of dialysis. The
characteristics of the study cohort stratified by the occurrence of
at least one CVE in the 2-year study period are described in
Table 1. Patients who experienced events in the first 2 years after
dialysis initiation tended to be older and were more frequently
male. They more often had vascular or diabetic causes for their
CKD, and this pattern was repeated in their pre-dialysis clinical
history, with a greater prevalence of the constituent CVE and
diabetes observed. Also the percentage of former smokers was
higher in those experiencing a CVE. Conversely, no geogra-
phical differences were apparent, and patients were similar with
regard to social relationship and current smoking status.
The characteristics of patients starting dialysis in FME
facilities and those starting dialysis elsewhere are shown in
Supplementary Table S1 online. With the exception of
geography (a higher proportion of FME facilities in Eastern
Europe are hospital based, hence the greater opportunity for
initiation therein) and diabetes prevalence (which may in turn
reflect geography), the populations were broadly similar.
Multiple events and mortality
Of the 1449 patients experiencing events, 905 (62.5%) experi-
enced a single event during the study period. The distribu-
tion of first constituent events was broadly similar to all
constituent events (coronary artery event, CAE: 26.5% vs.
28.8%; peripheral arterial event, PAE: 18.3% vs. 24.8%; con-
gestive heart failure event, CHFE: 23.9% vs. 20.0%; cerebro-
vascular event, CBE: 17.7% vs. 19.6%), with the exception of
sudden cardiac event, SCE (13.6% vs. 6.9%). This was largely
due to the exceptionally high mortality experienced by this
patient group, with 114 of 123 patients (92.7%) dying within
7 days of a first SCE (mostly consisting of sudden cardiac
death events) compared with 191 of 782 patients (24.4%)
Table 1 |Characteristics of the study cohort
Factor
CVE within 2 years
of HD initiation All (n=6308)
Yes (n=1449) No (n=4859)
Region, n (%)
West 742 (51.2) 2908 (59.8) 3650 (57.9)
East 707 (48.8) 1951 (40.2) 2658 (42.1)
Age (years)
Mean± s.d. 69.0± 11.8 63.1± 15.0 64.5± 14.5
Gender, n (%)
Female 552 (38.1) 1995 (41.1) 2547 (40.4)
Male 895 (61.8) 2860 (58.9) 3755 (59.5)
Missing 2 (0.1) 4 (0.1) 6 (0.1)
Marital status, n (%)
In a relationship 796 (54.9) 2744 (56.5) 3540 (56.1)
Not in a relationship 388 (26.8) 1099 (22.6) 1487 (23.6)
Missing 265 (18.3) 1016 (20.9) 1281 (20.3)
Smoking status, n (%)
Non-smoker 514 (35.5) 1787 (36.8) 2301 (36.5)
Former 321 (22.2) 742 (15.3) 1063 (16.9)
Current 111 (7.7) 373 (7.7) 484 (7.7)
Missing 503 (34.7) 1957 (40.3) 2460 (39.0)
Body mass index (kg/m2)
Mean± s.d. 27.1± 15.0 26.7± 11.2 26.8± 12.3
Missing, n (%) 373 (25.7) 1633 (33.6) 2006 (31.8)
Pre-dialysis disease history, n (%)
CAE 310 (21.4) 522 (10.7) 832 (13.2)
CBE 172 (11.9) 270 (5.6) 442 (7.0)
CHFE 150 (10.4) 281 (5.8) 431 (6.8)
PAE 160 (11.0) 244 (5.0) 404 (6.4)
SCE 3 (0.2) 4 (0.1) 7 (0.1)
Diabetes 535 (36.9) 1274 (26.2) 1809 (28.7)
Atrial fibrillation 68 (4.7) 150 (3.1) 218 (3.5)
Hypertension 721 (49.8) 2257 (46.4) 2978 (47.2)
Dyslipidemia 131 (9.0) 360 (7.4) 491 (7.8)
Chronic kidney disease etiology, n (%)
Hypertension/vascular 302 (20.8) 711 (14.6) 1013 (16.1)
Glomerulonephritis 89 (6.1) 500 (10.3) 589 (9.3)
Diabetic nephropathy 439 (30.3) 972 (20.0) 1411 (22.4)
Tubulointerstitial 147 (10.1) 514 (10.6) 661 (10.5)
Polycystic kidney disease 50 (3.5) 324 (6.7) 374 (5.9)
Miscellaneous/other 378 (26.1) 1599 (32.9) 1977 (31.3)
Invalid/missing 44 (3.0) 239 (4.9) 283 (4.5)
Abbreviations: CAE, coronary artery event; CBE, cerebrovascular event; CHFE,
congestive heart failure event; CVE, composite cardiovascular event; HD,
hemodialysis; PAE, peripheral arterial event; SCE, sudden cardiac event.
NB Tercile and quartile cut-offs supplied in Supplementary Table S5 online.
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experiencing other first constituent events. The number of
events experienced by the 544 patients with multiple events
ranged from 2 to 12, but most patients experienced 2 or 3 (with
these values forming the interquartile range). As expected,
associated mortality was lower, with 188 deaths occurring
within 7 days of the 956 subsequent events (19.7%), but
subsequent SCE events were still temporally associated with
high mortality (29/40; 72.5%). When considered sequentially,
subsequent events fell within the same constituent event class
in 522 instances (54.6%), but only the same ICD-10 block in
374 instances (39.1%), and both shared the same ICD-10 code
in 289 instances (30.2%). The median time between a
subsequent event and its predecessor was 19 days (interquartile
range 1–114 days); when the subsequent event occurred on the
same day (n= 216) it was a code from the same event class in
77 instances (35.6%), the same block in 33 instances (15.3%),
but never the same code, possibly due to the fact that a specific
code on 1 day was only counted once.
Rates of CVE
Table 2 shows first- and second-year rates of composite CVE
and five different CVE categories for all study patients and for
those initiating dialysis within or outside FME. The first-year
rate of composite CVE was 30.2 per 100 person-years (PYs)
and the second-year rate was 19.4 per 100 PYs. Individual
CVE constituent rates were generally higher during the first
year compared with the second year. In patients initiating HD
outside FME, the composite CVE rate was lower. This
difference was largely driven by differences in the more
common CAE and CHFE, but the event rates of the three
other categories also tended to be lower in those initiating
outside FME.
Figure 1 shows weekly composite CVE rates during the
first year after HD initiation. The CVE rate peaked sharply
during week 1, when it was more than 5-fold higher than
during week 2 (rate ratio (RR) 5.10 (95% confidence interval
(CI), 3.95–6.59)) and subsequently declined until week 4 to
achieve a relatively stable level during the remainder of the first
year. Monthly rates for the composite CVE and the five
different CVE constituents are illustrated in Figure 2. The
temporal pattern was very similar for CAE, CHFE, PAE, and
CBE, all of which showed highest incidence rates during the
first month. The event rate during month 1 was highest for CAE
(35.4 per 100 PY), followed by CHFE (28.2 per 100 PY), PAD
(22.6 per 100 PY), and CBE (15.1 per 100 PY). To define
periods of elevated risk (high-risk period), monthly event rates
during year 1 were related to the average event rate during year
2 (Table 3). Although the overall CVE high-risk period was
sustained until month 5 after dialysis initiation, the risk for CBE
and PAE was increased during the first month, but not the
second month, the risk for CAE was increased during the first
2 months, and the risk for CHFE until month 4. The event RR
was particularly high for CHFE, partly because the CHFE event
rate during the second year was lower than that for several other
CVEs. The risk for PAE was increased again during months 3–5
and 10. In contrast to other CVE categories, the incidence of
SCE followed a different pattern, with no early peak and a
significant increase compared with year 2 only in month 8.
Risk factor analysis
Figure 3 shows the results of univariate analyses testing the
association between demographic findings, patient history, clinical
findings, and dialysis parameters for the high-risk and post high-
risk periods (actual data in Supplementary Table S2 online).
Table 2 |Rates of composite CVE and CVE constituents during the first and second year in patients overall as well as in those
initiating dialysis within Fresenius Medical Care dialysis centers in Europe (FME) and outside FME facilities (Non-FME)
Groups of Patients, Events, Person-years at Risk and Rate per 100 Person-years (Rate (95% CI))
Subset Event First Year Second Year
Events Person-years Rate (95% CI) Events Person-years Rate (95% CI)
All CVE 1627 5396.6 30.2 (28.7–31.7) 796 4108.1 19.4 (18.1–20.8)
CAE 478 5396.6 8.9 (8.1–9.7) 218 4108.1 5.3 (4.6–6.1)
CHFE 348 5396.6 6.5 (5.8–7.2) 136 4108.1 3.3 (2.8–3.9)
PAE 418 5396.6 7.8 (7.0–8.5) 183 4108.1 4.5 (3.8–5.2)
CBE 288 5396.6 5.3 (4.7–6.0] 187 4108.1 4.6 (3.9–5.3)
SCE 95 5396.6 1.8 (1.4–2.2) 72 4108.1 1.8 (1.4–2.2)
FME CVE 1129 3392.6 33.3 (31.4–35.3) 563 2561.8 22.0 (20.2–23.9)
CAE 346 3392.6 10.2 (9.2–11.3) 141 2561.8 5.5 (4.6–6.5)
CHFE 241 3392.6 7.1 (6.2–8.1) 104 2561.8 4.1 (3.3–4.9)
PAE 300 3392.6 8.8 (7.9–9.9) 152 2561.8 5.9 (5.0–7.0)
CBE 182 3392.6 5.4 (4.6–6.2) 120 2561.8 4.7 (3.9–5.6)
SCE 60 3392.6 1.8 (1.4–2.3) 46 2561.8 1.8 (1.3–2.4)
Non-FME CVE 498 2004.0 24.9 (22.7–27.1) 233 1546.3 15.1 (13.2–17.1)
CAE 132 2004.0 6.6 (5.5–7.8) 77 1546.3 5.0 (3.9–6.2)
CHFE 107 2004.0 5.3 (4.4–6.5) 32 1546.3 2.1 (1.4–2.9)
PAE 118 2004.0 5.9 (4.9–7.1) 31 1546.3 2.0 (1.4–2.9)
CBE 106 2004.0 5.3 (4.3–6.4) 67 1546.3 4.3 (3.4–5.5)
SCE 35 2004.0 1.8 (1.2–2.4) 26 1546.3 1.7 (1.1–2.5)
Abbreviations: CAE, coronary artery event; CBE, cerebrovascular event; CHFE, congestive heart failure event; CI, confidence interval; CVE, composite cardiovascular event;
FME, Fresenius Medical Care dialysis centers in Europe; PAE, peripheral arterial event; SCE, sudden cardiac event; FME and Non-FME refers to the initiation of dialysis
healthcare environment.
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For most parameters we found consistency between the
direction of association during the high-risk and the post
high-risk period. Factors that were associated with increased
risk during both periods included increasing age, treatment in
Eastern Europe, former smoking, history of CVE, diabetes, or
atrial fibrillation, as well as diabetic and vascular nephropathy
as underlying disease. On the other hand, several dialysis
session–related parameters were associated with either increased
or decreased risk during the high-risk period, but not during
the post high-risk period. Low weekly dialysis dose, low pre-
dialysis blood pressure, and lower blood flow were associated
with increased risk during the high-risk period only, whereas
catheter use and higher net ultrafiltration were associated with
reduced risk during the high-risk period only. The results for
the constituent CVE were generally consistent with the com-
posite CVE, but with less statistical power to detect significant
differences (Supplementary Table S3 online).
Multivariate analysis showed the independent asso-
ciation between age, patient history, and dialysis parameters
with CVE in the high-risk period (Table 4; detailed data in
Supplementary Table S2 online). Low or high cumulative weekly
dialysis dose, high pre-dialysis systolic blood pressure, lower
blood flow, and lower net ultrafiltration were associated with
high early CVE risk. Only traditional CV risk factors (increasing
age, smoking, and CVE history) were independently associated
with CVE outside the high-risk period.
Additional analyses were undertaken to examine whether
the association between dialysis parameters and CVE in the
high-risk period was driven by differences in patients initiat-
ing dialysis in FME facilities or elsewhere (Supplementary
Figure S2 online) or by history of CVE (Supplementary Figure
S3 online). Despite restricted patient populations, results were
generally consistent, suggesting that these factors were not
major drivers for our findings.
As we did not have data on pre-dialysis care, we used
information on the use of graft and/or fistulas during the early
dialysis period (30 days) as a surrogate for a planned dialysis
start. The proportion of patients experiencing an event was
lower among those patients initiating within FME in whom
graft/fistula use was documented compared with those in
whom this was not the case (20.1% vs. 29.7%). However such
a difference was not found in patients initiating outside FME
(20.7% vs. 20.9%). Moreover, the monthly CVE pattern in
the FME and non-FME ‘graft/fistula’ and ‘no graft/fistula’
patient groups was similar, suggesting that a planned start
cannot prevent an increase in events soon after HD initiation.
DISCUSSION
The prevalence of most manifestations of CVD increases with
declining renal function and is particularly high in patients on
dialysis.9,14,15 The current study shows that the immediate
period following dialysis initiation is a very high CV risk
period, characterized by a much higher rate of major CVE
than the remainder of the first 2 years. Incidence rates that
were at least 3- and up to 8-fold higher than during the second
year on dialysis were found for vascular events affecting
coronary, cerebral, and peripheral arterial beds as well as heart
failure during the first month on dialysis. Analysis of the
composite CVE rate, which allowed a more granular analysis
of temporal trends showed, in fact, that the first week of HD
was associated with maximum CVE risk.
Although, to our knowledge, no previous studies have
determined CVE rates after dialysis onset, our findings are
consistent with several investigations that have highlighted an
increased mortality during the first year on dialysis4,9,16 and in
particular during the first 902,17 or 1203,7 days. Although data
on peak mortality rates are somewhat variable, one large cohort
study of over 300,000 patients observed highest mortality
rates within the first 2 weeks,5 which corroborates our notion
of an early high-risk period. Multiple causes may contribute
to early mortality on dialysis, but the majority are considered
of CV origin,3,6 which is also consistent with our observation
of elevated CVE rates after dialysis initiation. Several tradi-
tional risk factors, which we found to be associated with CVE
in the early phase after dialysis initiation, such as age, smoking
history, and CVE history were also identified to be associated
with early mortality in HD patients.2,3 Although we observed
a substantial overall mortality rate of 20% within 1 week
following a CVE, the majority of observed CVEs were not
immediately fatal, indicating a substantial increase in mor-
bidity early after dialysis initiation.
Theoretically, at least two different reasons may underlie
the increased rate of CVE following the onset of dialysis.
First, deterioration of renal function and/or the signs and
symptoms resulting in a decision to initiate dialysis may be
prodromal signs of the subsequent event. This appears
possible, e.g., for CHF events, but is less plausible for vascular
events, such as CBE, PAE, or CAE. The second and alternative
explanation would be that the initiation of dialysis triggers
CVE. In fact, the HD procedure itself has been recognized to
induce myocardial stunning and contractile dysfunction,18,19
endothelial dysfunction,20 oxidative stress,21 and inflammation.22
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Additional evidence suggests a direct temporal association of
CVE with the dialysis procedure. Thus, about one-third of all
strokes in dialysis patients were found to occur during or
shortly after HD treatment.12,23 Mortality rates and CVE
admission rates in a large US study of dialysis patients
were found to be associated with the dialysis schedule, with
highest rates on the day following the long interval.24
Irrespective of what causes temporal associations between
dialysis and CVE, additional factors must play a role that
increases the sensitivity during the first weeks and months
of dialysis. Although a decline in mortality rates may partly be
explained by the fact that high-risk patients die early and
less severely ill patients survive, similar considerations do
not sufficiently explain why the incidence rates for a variety of
different CVEs decline in parallel over time. The majority of
associations between risk factors and CVE were similar for the
high-risk and the post high-risk period, and we found little
evidence for factors that are only associated with CVE during
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Figure 2 |Monthly event rates for the composite cardiovascular events and constituent events.
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the high-risk period. For some aspects of CVD history at
baseline and specific etiologies of kidney disease, multivariate
analysis showed associations only during the early high-risk
period, and it is plausible that these factors lose their
relevance with time. In contrast to an early peak observed
for other CVE constituents, SCE was the only type of event
that followed a different pattern with no clear trend in
incidence rates during the first 2 years. We cannot explain this
Table 3 |High-risk periods for composite CVE and constituent events
Month Rate ratio (95% confidence interval)
CVE CAE CHFE PAE CBE SCE
1 5.32 (4.76–5.94) 6.73 (5.52–8.20) 8.57 (6.78–10.84) 5.09 (4.03–6.42) 3.28 (2.52–4.27) 0.79 (0.36–1.71]
2 1.47 (1.23–1.76) 1.85 (1.36–2.52) 1.87 (1.27–2.76) 1.21 (0.80–1.81) 1.21 (0.81–1.80) 0.92 (0.44–1.92)
3 1.32 (1.09–1.60) 1.10 (0.74–1.63) 2.00 (1.36–2.94) 1.81 (1.28–2.55) 0.90 (0.57–1.42) 0.60 (0.24–1.48)
4 1.27 (1.04–1.54) 0.97 (0.64–1.48) 2.07 (1.41–3.04) 1.67 (1.17–2.40] 0.83 (0.51–1.35] 0.74 (0.32–1.71)
5 1.25 (1.02–1.52) 1.25 (0.85–1.83) 0.93 (0.54–1.61) 1.77 (1.24–2.53) 0.86 (0.53–1.39) 1.53 (0.83–2.82)
6 1.04 (0.83–1.29) 1.20 (0.81–1.78) 0.75 (0.41–1.39) 1.27 (0.83–1.92) 0.78 (0.47–1.31) 1.18 (0.59–2.36)
7 1.10 (0.89–1.36) 1.10 (0.72–1.66) 0.91 (0.52–1.61) 1.14 (0.73–1.78) 1.26 (0.83–1.91) 0.94 (0.43–2.04)
8 1.08 (0.87–1.35) 0.99 (0.64–1.54) 1.30 (0.79–2.12) 1.07 (0.67–1.69) 0.67 (0.38–1.18) 2.07 (1.18–3.61)
9 1.12 (0.90–1.39) 1.24 (0.83–1.86) 1.03 (0.59–1.79) 1.20 (0.77–1.87) 1.00 (0.62–1.61) 0.99 (0.45–2.14)
10 1.23 (1.00–1.52) 1.22 (0.82–1.84) 1.20 (0.72–2.02) 1.67 (1.14–2.46) 0.92 (0.56–1.51) 1.01 (0.46–2.19)
11 0.96 (0.75–1.22) 0.87 (0.54–1.40) 0.85 (0.46–1.56) 1.31 (0.85–2.02) 0.83 (0.49–1.40) 0.88 (0.38–2.03)
12 0.93 (0.72–1.18) 0.89 (0.55–1.44) 0.63 (0.31–1.29) 1.11 (0.69–1.78) 1.02 (0.63–1.65) 0.90 (0.39–2.08)
Abbreviations: CAE, coronary artery event; CBE, cerebrovascular event; CHFE, congestive heart failure event; CVE, composite cardiovascular event; PAE, peripheral arterial
event; SCE, sudden cardiac event.
Boldface data represent the high-risk periods, during which the event rate remained significantly higher than the average event rate of the second year.
Area of residence (vs. Western Europe)
High-risk period Post high-risk period
Eastern Europe
Age (vs. <50 years)
50 to 59
60 to 69
70 to 79
80+
Gender (vs. female)
Male
In a relationship
Not in vs. in
Smoking status (vs. non-smoker)
Former smoker
Current smoker
BMI (vs. 18.5– <25)
<18.5
25 to <30
Disease history (vs. no history)
CVE
Diabetes
Atrial fibrillation
Hypertension
Dyslipidemia
CKD etiology (vs. glomerulonephritis)
Hypertension/vascular
Diabetic nephropathy
Tubulo-interstitial
Polycystic kidney disease
Miscellaneous/unknown
Cumulative weekly dialysis dose (vs. T2)
T1
T3
Catheter use (vs. none)
Catheter use
Pre-HD systolic BP (mmHg) (vs. 120 to <130)
<100
100 to <110
110 to <120
130 to <140
140 to <160
160
Actual blood flow (vs. Q4)
Q1
Q2
Q2
Q4
0.1 1 10 0.1 1 10
Odds ratio Odds ratio
Net ultrafiltration [l] (vs. Q1)
Q3
Q3
30
Figure 3 | Factors associated with composite cardiovascular events in the high-risk (left) and post high-risk (right) periods. Univariate
analysis (actual data shown in Supplementary Table S2 online). BMI, body mass index; CVE, cardiovascular events; HD, hemodialysis.
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difference but it is important to note that the accuracy of SCE
diagnosis is likely to be lower than that for other CVEs.15
Our study has several limitations. Primarily, overall event
rates were lower in patients initiating outside of FME
facilities. The reasons for this difference remain speculative,
but, given that many events occur within the first week after
dialysis initiation, it is possible that fatal and non-fatal events
occurred in patients initiating HD outside FME prior to
possible capture in the study, thus resulting in a healthier sub-
cohort (survival bias). Other differences related to patient
selection and treatment, however, cannot be excluded.
Despite this uncertainty, we chose to conduct further analysis
with the whole study cohort, rather than only those patients
initiating within FME, recognizing that this may lead to an
underestimation of event rates. Sensitivity analyses, examining
the effect of initiating within FME facilities or elsewhere,
showed that the inclusion of these patients had a minimal
impact on our risk factor analysis. Furthermore, CVEs
were assessed on the basis of ICD-10 codes and were not
adjudicated. In particular, distinguishing between heart failure
and volume overload is inherently difficult. We also do not
have data on several parameters that may have implications
for the interpretation of CVEs, including first presentation to
nephrologists, the level of renal function at dialysis initiation,
the specific indication for starting dialysis, or residual renal
function.25 As patients were enrolled at presentation to a
dialysis provider, we are unable to compare event rates after
dialysis initiation with event rates during the pre-dialysis
period. The AROii study represents a random sample drawn
from European FME centers to minimize selection bias, but
the findings may not be generalizable for patients under the
care of other providers. The strength of the study includes the
prospective establishment of an incident cohort of dialysis
patients, the continued coverage of patients with o7 days of
dialysis vintage,26 the broad geographic distribution across
several European countries, the assessment of fatal and non-
fatal events, and the possibility to assess and compare the
incidence rates of a whole spectrum of CVEs over time.
Although our findings clearly show that the early period
after dialysis initiation should be recognized as a high-risk
period that mandates increased surveillance, the optimal
mode of patient care during this period remains unclear. We
observed robust associations between CVE during the early
high-risk period with some dialysis-related parameters,
including higher and lower weekly dialysis dose, low actual
blood flow, and low net ultrafiltration. The latter observations
might suggest intensifying dialysis regimens early after dialysis
initiation rather than gradually increasing treatment intensity
over time. However, the association does not necessarily
imply causality, and, despite being statistically independent,
these parameters might also be surrogates for patients with
compromised CV function, in whom neither a higher dialysis
blood flow nor a higher rate of ultrafiltration could be
achieved. We were surprised to observe that catheter use was
associated with reduced risk during the high-risk period, as
previous studies have consistently shown that catheter use is
associated with early mortality.3,6 A large portion of catheter-
associated mortality is due to infections,27,28 and the asso-
ciation with CV morbidity may be less strong. In any case, the
finding was not confirmed in multivariate analysis, suggesting
that it is due to confounding by other factors. Unfortunately,
uncertainty also extends to acute management of CV complica-
tions and secondary prevention in patients on HD.15,29 Of
interest, it has been reported that a dedicated program of inten-
sive patient education, evaluation, and early clinical intervention
in patients new to dialysis reduced mortality within the first
120 days by 31% in a case–control study,30 suggesting that a
significant improvement in prognosis is feasible.
Finally, our findings also have to be considered in the context
of an ongoing debate about the optimal timing of dialysis
initiation and alternative treatment strategies. Prognosis of
patients on dialysis is inversely associated with the level of
residual renal function at dialysis initiation;31 however, strong
confounders of this association have been identified.32 More-
over, controlled studies and interventional trials in aggregate
favor a later rather than an earlier dialysis initiation.33,34
There is an increasing appeal for shared decision making for
dialysis initiation, based on evaluation of risks, benefits, quality
of life impact, and prognosis.35,36 Based on our findings we
believe that an increased risk for CVE after dialysis initiation
should be taken into account in such deliberations.
MATERIALS AND METHODS
The ARO CKD research initiative began in 2007, with the purpose of
improving HD patient outcomes in Europe through better under-
standing of patient morbidity and risk factors.37 The second ARO
cohort, AROii, comprises adult subjects presenting at 1 of over 300
participating FME facilities in 14 European countries and Turkey
between 1 January 2007 and 31 December 2009. Closed-cohort by
design, AROii comprises incident HD patients (o183 days since
commencing HD) with no history of renal transplantation. Data,
comprising detailed patient-level information on medical and drug
history, and longitudinal records of biochemical measurements
and medications, are captured electronically via the validated
FME European Clinical Database and supplied on a quarterly basis.
Table 4 | Factors associated with composite CVE in the
high-risk and post high-risk periods (summarized
multivariate analysis; actual data shown in Supplementary
Table S1 online)
Group High-risk period
Post high-risk
period
Demographic Increasing age Increasing age
Former smoker Former smoker
Current smoker
Clinical History of cardiovascular event History of cardio-
vascular event
History of atrial fibrillation
CKD etiology of hypertension/vascular
disorders
CKD etiology of diabetic nephropathy
Dialysis Higher or lower cumulative weekly
dialysis dose
High pre-dialysis systolic blood pressure
Lower actual blood flow
Lower net ultrafiltration
Abbreviations: CKD, chronic kidney disease; CVE, cardiovascular event.
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All ethical and regulatory obligations concerning the use of patient
data are met at each participating site. The patient population was
restricted further in the current study to include patients with a
dialysis vintage of o7 days on admission to an FME clinic, or who
initiated within 365 days of admission. All patients were required to
have at least one dialysis session in FME facilities.
Initial descriptive statistics were analyzed to describe the study
population at baseline and the distributions of the study confounders.
Continuous variables were described using mean and s.d., median, 25th
and 75th percentiles, and minimum and maximum values. Skewed
variables were described using a median and range, or categorized into
meaningful categories at which point categorical data analysis was
applied. Categorical data were reported as counts and frequencies.
The primary end point for analyses, the composite CVE, com-
prised fatal or non-fatal constituent CAE, CBE, PAE, CHFE, and SCE
based on ICD-10 coded comorbidities data (Supplementary Table S4
online). Crude event rates were calculated for each week (for the
composite CVE) and month of dialysis vintage (for all outcomes)
during the first 2 years. In each instance, patients accrued time at risk
from the beginning of the month of interest until they experienced
the event of interest or were censored (lost-to-follow-up (445 days
without continuous dialysis at an FME facility), renal transplanta-
tion, or the end of that month, whichever came first). The event
rate, ̂r, was estimated as:
̂r ¼ Y
e
where Y is the observed number of events, and e is the exposure
period in PY.38 Exact 95% Poisson CIs were derived and presented
as:
Y 1 ¼
w22Y ;a=2
2e
Yu ¼
w22ðYþ1Þ;1a=2
2e
where Y is the observed number of events, Yl and Yu are lower and
upper CIs for Y, respectively, and w2v;a is the χ
2 quartile for upper tail
probability α(0.05) on v degrees of freedom.39 An objective approach
was taken to define the high-risk period, where RRs were calculated for
each month in the first year using the second-year rate as the reference
time period. The high-risk period was defined as the period during
which the risk was significantly elevated as compared with the second
year. In other words, the high-risk period extended to the point where
the lower CI for the RR included one. The post high-risk period
represented the period from the end of the high-risk period until the
end of the first year. RRs were calculated on the basis of the formula:
RR ¼ Y 1=e1
Y 2=e2
where Y1 and Y2 are the number of events in any given month and the
second year, respectively, and e1 and e2 are the PYs at-risk for the same
time points; 95% CIs for the RR were calculated on the basis of the
formula log(RR)± 1.96× SE[log(RR)], where SE[log(RR)] (the stan-
dard error of the log RR) was calculated40 as:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1=Y 1 þ 1=Y 2
p
Logistic regression models were fitted to the data to determine
separately potential predictors of events in high-risk and post high-risk
periods. Patients experiencing the outcome of interest (coded ‘1’ in the
outcome variable) were compared with patients who did not (coded ‘0’
in the outcome variable) as of the end of the period, with odds ratios
and 95% CIs calculated for each explanatory variable (Table 1).
Multivariate logistic regression was applied to control for confounding.
Potential predictors—those associated with the outcome at the 95%
level—were added and removed from the model in a stepwise manner,
where 10% and 5% significance levels were used to determine variable
entry and retention, respectively. Logistical regression models rather
than a Cox proportional hazards model–based approach were used, as
patients were defined by their outcome (rather than exposure).
Moreover, regression coefficients obtained from both approaches
are similar, when—as in our study—the follow-up time is short.41
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Figure S1. Patient's dialysis vintage on recruitment to the AROii
cohort. Insert shows the hemodialysis peri–initiation period in detail.
Figure S2. Factors associated with composite CVE in the high–risk
period by (FME) initiation status (univariate analysis).
Figure S3. Factors associated with composite CVE in the high–risk
period by history of CVE (univariate analysis).
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Fresenius Medical Care European (FME) facility or elsewhere.
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Table S2. Factors associated with composite CVEs in the high-risk and
post high-risk periods (univariate and multivariate analysis). Estimates
where 95% confidence intervals do not include one are emboldened.
Table S3. Factors associated with the constituent events in the high-
risk and post high-risk periods (univariate analysis). Estimates where
95% confidence intervals do not include one are emboldened.
Depending on the limited number of observed sudden cardiac events
(SCEs), the analysis is not provided for this constituent event category.
Table S4. Cardiovascular disease event codes.
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Supplementary material is linked to the online version of the paper at
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